The surprise abandonment of a Japan project by Las Vegas Sands is just the latest indication of how red tape is turning suitors away.
India's drugmakers aim to manufacture generic versions of any coronavirus 'cure', even before the full findings as to how effective they are.
Slowing infections in South Korea and stimulus in Singapore and Japan pushed stocks higher Monday, but tighter restrictions will hurt Asia's economies.
With Tokyo's coronavirus case count accelerating, investors are bracing themselves in case the still-bustling capital goes into lockdown.
Japan is a leader in pharmaceuticals and has three companies working overtime to develop treatments for Covid-19.
Fujifilm Holdings has a promising drug that seems to work in improving the outcome for coronavirus patients in China and Japan, though Avigan is a treatment not a cure.
There are country-specific reasons why Australia, India and Thailand are leading Asia's plunge, but the whole region is in recession, S&P correctly says.
Stimulus measures and government bans have opposing effects and are driving equity markets forward and back in unpredictable ways.
These 6 companies are due for inclusion in Japan's smartest index, which should lead for 7% outperformance between now and July.
I'll stick to the three-pronged approach... the Rebound group, the Virus group, and the Revenue group.